244 - Challenging Vaccine Issues: Beyond the Guidelines

Wednesday, October 22, 2025

1:45 PM - 3:00 PM US ET

Location: Sidney J. Marcus Auditorium

CME Credits: Maximum of 1.25 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 1.25 hours of MOC Credit
CNE Credits: Maximum of 1.25 hours of ANCC Credit
ACPE Credits: ACPE 1.25 knowledge-based contact hours of pharmacy CE
ACPE Number: JA0007082-9999-24-002-L01-P
PACE Credits: Maximum of 1 of PACE contact hours
CE Broker: Maximum of 1 CE broker credit hours

Interactive Moderator(s)

Catherine Mary Healy, MD, FIDSA (she/her/hers)

Associate Professor of Pediatrics
Baylor College of Medicine
Houston, TX, United States

Slides
Flor Munoz, MD

Associate Professor of Pediatrics
Pediatrics
Baylor College of Medicine Houston
Dallas, Texas, United States

Panelist(s)

Jennifer Whitaker, MD, MS

Assistant Professor of Medicine
Baylor College of Medicine
Houston, TX, United States
Christina Rostad, MD

Associate Professor of Pediatrics
Department of Pediatrics, Division of Infectious Diseases
Emory University School of Medicine and Children's Healthcare of Atlanta
Atlanta, GA, United States
Robert Frenck, Jr., MD

Professor of Pediatrics
Infectious Diseases
Cincinnati Children's Hospital
Cincinnati, OH, United States

Disclosure(s):

Catherine Mary Healy, MD, FIDSA: Dexcom, Inc: Stocks/Bonds (Public Company); Hillevax, Inc: Advisor/Consultant; Intuitive Surgical, Inc: Stocks/Bonds (Public Company); Quidel Diagnostics: Stocks/Bonds (Public Company); UpToDate Wolters Kluwer Health: Honoraria; Vindico CME: Honoraria

Flor M. Munoz, MD: Moderna: Board Member; Pfizer: Board Member, Grant/Research Support; Sanofi: Advisor/Consultant

Jennifer Whitaker, MD, MS: Pfizer, Inc.: Grant/Research Support

Christina A. Rostad, MD: Janssen: Grant/Research Support; Meissa Vaccines: Grant/Research Support, International PCT Application No. PCT/US2016/058976, filed 12/28/2016 by Emory University; Merck: Grant/Research Support; Micron: Grant/Research Support; Moderna, Inc: Grant/Research Support; Pfizer, Inc.: Grant/Research Support; Sanofi: Grant/Research Support, Sanofi provided investigational product (nirsevimab) for the conduct of this study.

Robert W. Frenck, MD, Jr.: Cyanvac: Grant/Research Support; LimmaTech: Grant/Research Support; Moderna: Advisor/Consultant; Pfizer: Grant/Research Support; Vaxart: Advisor/Consultant; Vaxcyte: Advisor/Consultant

Learning Objectives:

At the conclusion of this session, participants will be able to:

review the evidence and rationale behind vaccine recommendations;
discuss some updated vaccine guidelines against specific vaccine-preventable diseases;
describe approaches to real-life clinical vaccination questions where guidelines are open to differing interpretation;
describe the rationale and evidence behind specific guidelines